Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 4Other hematologic neoplasm 3Thoracic 2Gynecologic 2Plasma cell 1Other solid neoplasm 1Myeloid 1Lymphoid 1Genitourinary 1Gastrointestinal 1CNS 1Breast 1

Conditions

Triple Negative Breast Neoplasms 1Small Cell Lung Carcinoma 1Ovarian Neoplasms 1Leukemia, Myeloid, Acute 1Colorectal Neoplasms 1

Interventions

Trastuzumab 379Paclitaxel 369Cyclophosphamide 338Docetaxel 314Capecitabine 198Doxorubicin 196Letrozole 184Tamoxifen 154Carboplatin 153Fulvestrant 136Bevacizumab 129Anastrozole 120exemestane 119Lapatinib 117Epirubicin 116Gemcitabine 112Radiotherapy 107palbociclib 94Exercise 87Fluorouracil 83Vinorelbine 82Surveys and Questionnaires 81pertuzumab 77Albumin-Bound Paclitaxel 76Filgrastim 71130-nm albumin-bound paclitaxel 64pembrolizumab 63Everolimus 59Cisplatin 59eribulin 58

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Monatide (IMS 3015) × Breast × Clear all
NCT03761914 2024-11-19

Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers

Sellas Life Sciences Group

Phase 1/2 Completed
26 enrolled 14 charts
BreastGastrointestinalGynecologicOther hematologic neoplasmThoracic

Ovarian Neoplasms, Colorectal Neoplasms, Leukemia, Myeloid, Acute, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡